FDA expected to approve Pfizer-BioNTech's COVID-19 vaccine by early September: NYT
- The FDA is said to be expected to approve the Pfizer-BioNTech COVID-19
vaccineby early September.
- The "sprint" toward formal approval was first reported by STAT.
- Formal approval, rather than emergency authorization, could build public confidence in the vaccine.
The Food and Drug Administration is working to approve the Pfizer-BioNTech COVID-19 vaccine by early September, according to The New York Times.
The "sprint" toward formal approval was first reported by STAT.
The pharmaceutical company Pfizer filed its application with the FDA on May 7, and the Times report cited unnamed sources as saying the health regulator was hoping to finish its approval process by Labor Day weekend. As The Times noted, numerous employers are preparing to institute vaccine mandates once the Pfizer-BioNTech vaccine is approved.
Pressure has mounted on the FDA to safely approve the Pfizer-BioNTech vaccine as the Delta
The Pfizer-BioNTech vaccine, along with COVID-19 vaccines from Johnson & Johnson and Moderna, currently have emergency-use authorization for use in the US as long as COVID-19 remains a threat.
Some expect full approval - rather than the emergency authorization - to boost public confidence in the jab and persuade some people to get vaccinated.
- Girish Mathrubootham, the son of a retired bank officer who built a $13 billion company in just 10 years
- A couple who traveled to 48 states in an RV share 17 things they would never go on a trip without
- The Taliban is bringing back executions and cutting off hands as punishment after retaking control of Afghanistan
- DC vs RR: Who will win today’s IPL match?
- We asked three spacetech entrepreneurs what it takes to enter the field and they listed out the opportunities
- Ethereum’s scaling issues strike again as TIME Magazine’s NFTs sell for 30 times their price
- Best baby swing cradle and chair in India
- China's FUD drags down Bitcoin, Ether and other cryptocurrencies yet again